Sanofi’s tolebrutinib has been shown to delay disability progression in multiple sclerosis (MS) patients, according to phase ...

Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation ...

Tolebrutinib, an experimental drug, slowed disability progression in advanced MS by 31% in a major trial, offering hope for ...

Sanofi announces tolebrutinib phase 3 study data published in NEJM shows benefit on disability progression in multiple sclerosis: Paris Thursday, April 10, 2025, 10:00 Hrs [IST] T ...

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine ...

Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing ...

Results of the Phase III HERCULES trial suggest the first potential treatment option for a form of multiple sclerosis.

AI: For example, advanced diagnostic tests such as CT scans or MRI were more often recommended for high-income patients, ...

The AI models occasionally altered decisions based on patients’ personal characteristics, affecting priority for care and ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...